Trump orders ibogaine and other psychedelics on fast track at FDA
Alcoholism & Drug Abuse Weekly April 24, 2026 DOI: 10.1002/adaw.34891 via OpenAlex
Summary
AI-generated from the abstractPresident Donald Trump signed an executive order on April 17 directing the FDA to create a pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds. The order also requires HHS to allocate $50 million through ARPA-H to match state government investments in research on psychedelic programs for populations with serious mental illness.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Keywords | Fast track Executive order Mental health Track disk drive Human services |
| Key finding | The executive order directs the FDA to establish a pathway for eligible patients to access investigational psychedelic drugs and allocates $50 million through ARPA-H to match state investments in psychedelic research for serious mental illness. |
Abstract
On April 17, President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to “establish a pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds.” While citing the need for solutions to treatment‐resistant mental illness, Trump also required the U.S. Department of Health and Human Services (HHS) to allocate $50 million through the Advanced Research Projects for Health (ARPA‐H) program to match investments made by state governments to advance research into psychedelic programs for populations with serious mental illness.